Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ResoTher Pharma","sponsor":"European Innovation Council","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"ResoTher Pharma Receives a \u20ac2.5 Million Grant from European Innovation Council (EIC) to Support a Phase 2a Clinical Study of their Lead Candidate RTP-026 for Myocardial Infarction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by ResoTher Pharma

    Menu

    ResoTher Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ResoTher Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ResoTher Pharma Receives a €2.5 Million Grant from European Innovation Council (EIC) to Support a Phase 2a Clinical Study of their Lead Candidate RTP-026 for Myocardial I...

              Details:

              The funding will be used to support the development of the company's lead compound, RTP-026, an IP-protected analogue of the N-terminus of the Annexin A1 protein, in a Phase 2a clinical study in Myocardial Infarction.

              Lead Product(s): RTP-026

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: RTP-026

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: European Innovation Council

              Deal Size: $2.7 million Upfront Cash: Undisclosed

              Deal Type: Funding November 06, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY